<DOC>
	<DOCNO>NCT00859105</DOCNO>
	<brief_summary>Treatment , Randomized , Double Blind ( Subject , Caregiver , Investigator , Outcomes Assessor ) , Placebo Control , Parallel Assignment , Bio-equivalence Study</brief_summary>
	<brief_title>A Randomized , Double-Blind , Parallel-Group , Vehicle-Controlled Therapeutic Equivalence Study Three Imiquimod Cream 5 % Treatments Patients With Actinic Keratosis</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<mesh_term>Imiquimod</mesh_term>
	<criteria>Patients must 4 8 clinically diagnose , nonhyperkeratotic , nonhypertrophic AK lesion within 25 cm2 contiguous treatment area either face bald scalp Women either must 1 year postmenopausal , surgically sterile , agree use medically accept form birth control Free systemic dermatological disorder Any skin type race , provide skin pigmentation allow discernment erythema Basal cell squamous cell carcinoma , possible confound skin condition ( face scalp ) History cutaneous hyperreactivity facial irritation topical product Engaging activity involve excessive prolonged exposure sunlight Receiving systemic cancer chemotherapy , psoralen plus UVA therapy , UVB therapy , laser abrasion , dermabrasion , glycolic acid , chemical peel 6 month prior study entry Currently use use systemic steroid 2 month prior study Currently use use treatment area overthecounter retinol product , corticosteroid , cryosurgery , curettage , 5fluorouracil , topical actinic keratosis treatment 28 day prior randomization Pregnant nursing mother History allergy sensitivity imiquimod related compound component formulation Taking immunosuppressant medication</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2009</verification_date>
</DOC>